Understand the source comparison
Best Peptides for Post Concussion Syndrome: Research Comparison
Cerebrolysin BDNF/NGF mimetic. Reduces apoptosis, promotes synaptic plasticity Acute (0–14 days) Six RCTs, n=1,773 TBI patients. 23% mortality reduction, improved GOS scores Requires IV administration, expensive, temperature-sensitive Dihexa HGF potentiation.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF/NGF mimetic. Reduces apoptosis, promotes synaptic plasticity
- Acute (0–14 days)
- Six RCTs, n=1,773 TBI patients. 23% mortality reduction, improved GOS scores
- Requires IV administration, expensive, temperature-sensitive
- Dihexa
- HGF potentiation. Amplifies BDNF transcription, increases synaptogenesis 40–60%
- Chronic (2+ months)
- Preclinical only. No human TBI trials published as of 2026
- Dosing protocols not standardised, BBB penetration unverified in humans
- P21
- CNTF mimetic. Promotes oligodendrocyte survival, axonal remyelination
- Subacute to chronic (2–12 weeks)
- Rodent TBI models show 35% cognitive improvement vs controls
- Human data absent, intranasal delivery complicates dosing accuracy
- Thymalin
- Microglial M1→M2 polarisation. Reduces IL-1β, TNF-α, upregulates IL-10
- Acute to subacute (0–8 weeks)
- Russian stroke trials show 30–40% inflammatory marker reduction
- No published TBI-specific trials, subcutaneous injection required
- MK-677
- GH secretagogue. Upregulates IGF-1, restores BBB tight junctions
- Acute to subacute (0–4 weeks)
- Rodent models show 40% reduction in BBB permeability post-TBI
- Oral bioavailability unverified in TBI context, potential insulin resistance at chronic doses